Search

Dr. Dalton Wolfe is a Scientist at Parkwood Institute (SJHC London) and the leader of the R2P (Research 2 Practice) team that integrates clinical and research efforts to improve care and clinical outcomes. His primary research interest is in the area of knowledge mobilization and best practice implementation with a focus on physical activity and activity-based therapies in spinal cord injury and brain injury rehabilitation. He co-leads the Ontario SCI Implementation, Evaluation and Quality Care Consortium which focuses on implementation of quality indicators towards the enhancement of care across the 5-academic health centres involved in SCI rehabilitation in the province of Ontario. As part of the Parkwood Rehabilitation Innovations in Mobility Enhancement (PRIME) initiative he is focused on enhancing clinical decision-making to improve locomotor and other movement-related outcomes with activity-based therapies such as robotic, manual and FES-assisted therapies. As with many of the R2P initiatives this involves implementation science and participatory research methods to put in place practice-based research infrastructure that enables iterative knowledge generation as well as implementation.   Dr. Wolfe Is currently accepting students at the Masters, Doctoral, and post-doctoral levels.

Latest News: https://www.lawsonresearch.ca/lawsonlink/prime-team

Dr. Keast is a native of London Ontario, graduating from Western University with a Master's Degree in Chemistry. He taught High School for eleven years before entering medicine at Queens University graduating in 1985. He practiced family practice for 25 years before focusing his practice in Wound Care. He is a past president and a founding board member of the Canadian Association of Wound Care.

He is currently the president of the World Alliance for Wound and Lymphedema Care and Director of the Canadian Lymphedema Framework.  Dr. Keast is an internationally recognized educator and has participated on many national and international advisory panels.

Degrees and Diplomas

1997       Postgraduate Training (Residency in Psychiatry), Sheppard Pratt Health Systems, Baltimore, Maryland, United States

1993       MD, Michigan State University College of Human Medicine, Doctor (Medical), East Lansing, Michigan, United States

1983       BA, New College, Honors College of University of South Florida, Bachelor’s, Honours, Major in Philosophy, Sarasota, Florida, United States

Research Training

1997 - 2000       Clinical Research Fellowship, National Institute of Mental Health, Biological Psychiatry Branch, Senior Staff Fellow, Supervisor:  Dr. Robert M. Post, Bethesda, Maryland, United States

Qualifications, Certifications and Licenses

2005 - present   The College of Physicians and Surgeon of Ontario

2005 - present   The Royal College of Physicians and Surgeons Canada

1998 - 2018       American Board of Psychiatry and Neurology, Certified, United States

2005 - 2009       Maryland Board of Physicians, License, Maryland, United States

Emma Duerden, PhD is a Canada Research Chair in Neuroscience and Learning Disorders. She is an Assistant Professor in Applied Psychology in the Faculty of Education and a member of the Brain & Mind Institute at Western University, Canada. She is also a Scientist in the Maternal, Fetal and Newborn Health Division at the Children's Health Research Institute. Her research examines early life stress (e.g., pain, brain injury) and the association with brain development and cognitive outcomes in infants and children.

Dr. Wisenberg is a cardiologist at London Health Sciences Centre, who was trained in the seminal days of nuclear cardiology. He participated in the early human trials at UCLA assessing the role of PET in assessing regional myocardial perfusion. His career has involved the use of a number of imaging modalities including SPECT, PET, MRI, and CT with specific reference to their role in assessing response to therapy and in guiding the management of cardiac patients. His current research focus is on determining the optimum time to inject stem cells to maximize the likelihood for myocardial regeneration, and to improve means of prolonging the residence time of the stem cells in the heart so that they can exert the greatest degree of repair.